Article

Mammalian cells-based platforms for the generation of SARS-CoV-2 virus-like particles

2023-07-25

Abstract excerpt

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19. Though many COVID-19 vaccines have been developed, most of them are delivered via intramuscular injection and thus confer relatively weak mucosal immunity against the natural infection. Virus-Like Particles (VLPs) are self-assembled nanostructures composed of key viral structural proteins, that mimic the wild-type viru...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bd211504-9f19-5c3f-bc67-88edae49caec
DOI: 10.1101/2023.07.24.550415

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mammalian cells-based platforms for the generation of SARS-CoV-2 virus-like particlesDOI 10.1101/2023.07.24.550415Read

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriersSemantic proximity Read

Rapid and Scalable Production of Functional SARS-CoV-2 Virus-like Particles (VLPs) by a Stable HEK293 Cell PoolSemantic proximity Read

Efficient production of Moloney murine leukemia virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike proteinSemantic proximity Read

A novel cell culture system modeling the SARS-CoV-2 life cycleSemantic proximity Read

Virus‐like particles as powerful vaccination strategy against human virusesSemantic proximity Read

ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccinesSemantic proximity Read

Virus-like particles: flexible platforms for vaccine developmentSemantic proximity Read

SARS-CoV-2 Virus like Particles produced by a single recombinant baculovirus generate potent neutralizing antibody that protects against variant challengeSemantic proximity Read

Next‐Generation Vaccines: Nanovaccines in the Fight against SARS‐CoV‐2 Virus and beyond SARS‐CoV‐2Semantic proximity Read

Platforms, advances, and technical challenges in virus-like particles-based vaccinesSemantic proximity Read

Advances and challenges in enveloped virus-like particle (VLP)-based vaccinesSemantic proximity Read

Functional Severe Acute Respiratory Syndrome Coronavirus 2 Virus-Like Particles From Insect CellsSemantic proximity Read